WO2022215046A1 - Procédé de détermination de l'efficacité d'un traitement sur un visage - Google Patents

Procédé de détermination de l'efficacité d'un traitement sur un visage Download PDF

Info

Publication number
WO2022215046A1
WO2022215046A1 PCT/IB2022/053319 IB2022053319W WO2022215046A1 WO 2022215046 A1 WO2022215046 A1 WO 2022215046A1 IB 2022053319 W IB2022053319 W IB 2022053319W WO 2022215046 A1 WO2022215046 A1 WO 2022215046A1
Authority
WO
WIPO (PCT)
Prior art keywords
face
product
treatment
angle
axis
Prior art date
Application number
PCT/IB2022/053319
Other languages
English (en)
Inventor
Brenda EDISON
Thomas SHYR
Neena Tierney
Original Assignee
Johnson & Johnson Consumer Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Johnson & Johnson Consumer Inc. filed Critical Johnson & Johnson Consumer Inc.
Priority to CA3216239A priority Critical patent/CA3216239A1/fr
Priority to KR1020237037982A priority patent/KR20230169196A/ko
Priority to US18/286,162 priority patent/US20240188887A1/en
Priority to CN202280033843.4A priority patent/CN117377430A/zh
Priority to MX2023011926A priority patent/MX2023011926A/es
Priority to EP22721123.2A priority patent/EP4319632A1/fr
Priority to BR112023020813A priority patent/BR112023020813A2/pt
Priority to JP2023561745A priority patent/JP2024515566A/ja
Priority to AU2022253591A priority patent/AU2022253591A1/en
Publication of WO2022215046A1 publication Critical patent/WO2022215046A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00—Measuring for diagnostic purposes; Identification of persons
    • A61B5/103—Detecting, measuring or recording devices for testing the shape, pattern, colour, size or movement of the body or parts thereof, for diagnostic purposes
    • A61B5/107—Measuring physical dimensions, e.g. size of the entire body or parts thereof
    • A61B5/1071—Measuring physical dimensions, e.g. size of the entire body or parts thereof measuring angles, e.g. using goniometers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00—Measuring for diagnostic purposes; Identification of persons
    • A61B5/0059—Measuring for diagnostic purposes; Identification of persons using light, e.g. diagnosis by transillumination, diascopy, fluorescence
    • A61B5/0077—Devices for viewing the surface of the body, e.g. camera, magnifying lens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00—Measuring for diagnostic purposes; Identification of persons
    • A61B5/103—Detecting, measuring or recording devices for testing the shape, pattern, colour, size or movement of the body or parts thereof, for diagnostic purposes
    • A61B5/107—Measuring physical dimensions, e.g. size of the entire body or parts thereof
    • A61B5/1079—Measuring physical dimensions, e.g. size of the entire body or parts thereof using optical or photographic means
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00—Measuring for diagnostic purposes; Identification of persons
    • A61B5/48—Other medical applications
    • A61B5/4848—Monitoring or testing the effects of treatment, e.g. of medication
    • G—PHYSICS
    • G06—COMPUTING; CALCULATING OR COUNTING
    • G06T—IMAGE DATA PROCESSING OR GENERATION, IN GENERAL
    • G06T7/00—Image analysis
    • G06T7/0002—Inspection of images, e.g. flaw detection
    • G06T7/0012—Biomedical image inspection
    • G06T7/0014—Biomedical image inspection using an image reference approach
    • G06T7/0016—Biomedical image inspection using an image reference approach involving temporal comparison
    • G—PHYSICS
    • G06—COMPUTING; CALCULATING OR COUNTING
    • G06T—IMAGE DATA PROCESSING OR GENERATION, IN GENERAL
    • G06T7/00—Image analysis
    • G06T7/60—Analysis of geometric attributes
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
    • G16H20/00—ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance
    • G16H20/10—ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance relating to drugs or medications, e.g. for ensuring correct administration to patients
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
    • G16H20/00—ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance
    • G16H20/40—ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance relating to mechanical, radiation or invasive therapies, e.g. surgery, laser therapy, dialysis or acupuncture
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00—Measuring for diagnostic purposes; Identification of persons
    • A61B5/48—Other medical applications
    • A61B5/4836—Diagnosis combined with treatment in closed-loop systems or methods
    • G—PHYSICS
    • G06—COMPUTING; CALCULATING OR COUNTING
    • G06T—IMAGE DATA PROCESSING OR GENERATION, IN GENERAL
    • G06T2207/00—Indexing scheme for image analysis or image enhancement
    • G06T2207/30—Subject of image; Context of image processing
    • G06T2207/30004—Biomedical image processing
    • G—PHYSICS
    • G06—COMPUTING; CALCULATING OR COUNTING
    • G06T—IMAGE DATA PROCESSING OR GENERATION, IN GENERAL
    • G06T2207/00—Indexing scheme for image analysis or image enhancement
    • G06T2207/30—Subject of image; Context of image processing
    • G06T2207/30196—Human being; Person
    • G06T2207/30201—Face

Definitions

  • the present invention relates to methods of assessing improvement of skin by the use of various products, and making modifications to the use thereof as needed or desired.
  • the triangle of youth is a substantially triangular shape as measured by the lines formed between the cheek bones to the center of the chin.
  • a “youthful” triangle is considered with an inverted triangular shape, where the lines connecting each cheek bone with the center of the chin form a smaller angle (i.e. , high cheekbones, full cheeks and a well- defined jawline).
  • a more aged triangle is associated with a wider angle, and may be considered to have flipped to form the “pyramid of age”, as measured from the sides of the jawline to the center of the eyes.
  • One aspect of the invention pertains to a method of determining the effectiveness of a treatment on a face having a jawline and a chin, the method comprising:
  • the first front-facing image of the face after the treatment is taken at least one week after the treatment.
  • additional front facing images are provided and steps (b)-(f) are repeated at regular intervals.
  • additional front-facing images are provided and steps (b)-(f) are repeated during a treatment period.
  • the method further comprises (j) comparing the angle between the x-axis and the facial landmark line before the treatment to the angle between the x-axis and the facial landmark line after the treatment.
  • the treatment comprises application of an anti-aging product.
  • the anti-aging product is a cream or lotion.
  • the anti-aging product comprises one or more anti-aging active ingredients.
  • the product is applied as part of a regimen.
  • the product and/or the regimen is modified after (i).
  • the modification is selected from the group consisting of using a different product in substitution for the first product, using a new product in addition to the first product, changing the regimen, or changing the amount of time the product is left on the face, and combinations thereof.
  • the treatment comprises an anti-aging procedure.
  • the anti-aging procedure is selected from the group consisting of injection of one or more fillers, plastic surgery, a peel treatment, a laser treatment, light treatments, and combinations thereof.
  • FIGS. 1 A-B show a representation of a younger face and an older face, respectively;
  • FIGS. 2A-B show a representation of a face with a depiction of jawline angle and with various facial landmarks, respectively;
  • FIG. 3 shows the calculated average jawline angle for various age brackets based on analysis of frontal images from the publicly available CACD dataset
  • FIG. 4 shows the calculated average jawline angle for each age bracket based on analysis of frontal images from the publicly available FairFace dataset.
  • the present invention relates to methods of determining the effectiveness of a product or regimen of using a product, and further relates to a method of using a product or modifying use of a product to effectively provide a benefit to the user.
  • the desired benefit is referred to generally as reducing the signs of aging in the face of the user, which is described in more detail below. Any product or products that are intended to provide this benefit may be useful in the present invention, including certain anti-aging products described below.
  • one aspect of the invention pertains to a method of determining the effectiveness of a treatment on a face having a jawline and a chin, the method comprising:
  • treatment refers to any activity intended to have an effect on the skin of the face, particularly an anti-aging affect.
  • treatments include, but are not limited to application of an anti-aging product, or an anti-aging procedure as further detailed below.
  • front-facing image refers to an image of a face taken from the front such that the outline of either side of the face is substantially symmetrical (correcting for any naturally occurring asymmetries of the face).
  • front-facing images that are being compared should match as closely as possible in terms of symmetry.
  • center position of the chin of the face refers to the lowest point appearing on the face in the front-facing image.
  • center of the face refers to the midpoint of the widest part of the face. In further embodiments, the midpoint may be calculated as the average across multiple pairs of points on the right and left side of the face. That is, pairs of points along the jawline above and/or below the widest point of the face may be averaged out to calculate the center of the face.
  • facial landmark refers to any point selected along the jawline of a face.
  • the human face has a number of features, and demonstrates various signs of aging as the individual grows older. Signs of aging include, for example, flattening of cheeks, drooping of skin over the cheeks, sagging of the jawline, lack of definition in the jawline, and fat accumulating between the neck and chin.
  • a face that is deemed to have a youthful appearance is referred to as demonstrating the “triangle of youth”, which is defined by lines connecting the cheekbones and center of chin.
  • a face that is deemed to have a more aged appearance is referred to as demonstrating a pyramid of aging, which is defined by the lines connecting the sides of the jaw to the center of the eyes.
  • FIG. 1A More youthful and younger-looking faces tend to have a more “reverse pyramidal” shape, associated with the triangle described above.
  • This youthful shape is associated with a bigger angle, described below and shown in FIG. 1A.
  • the face shown in FIG. 1 A has a larger angle as measured up the face from the chin, while the face shown in FIG. 1 B has a flatter angle as measured from the chin.
  • the smaller, flatter angle of the face shown in FIG. 1 B is associated with a more aged appearance. As this angle is increased, the effect is to reduce the visual sign of aging, and therefore provide the user with a more “youthful” look and appearance.
  • the jawline angle may also be effective as a measurement tool for age estimation, or to determine the effective improvement in age appearance after application of a product or after a treatment period.
  • the jawline angle methods described herein are effective as a method to evaluate the user’s face and determine whether an anti-aging treatment is needed or desired, for example, if the angle begins to decrease over time. In some instances, this may be useful as a pre-aging tool, helping a user even when that user has not previously undergone an anti-aging treatment or regimen. It is an objective of the present invention to evaluate the angle, described below, and determine its efficacy in reducing the sign of aging associated with the triangle of youth. By determining efficacy, modifications to a treatment may be made. This is described below in more detail.
  • Some features of more youthful looking skin include more defined cheek bones, a volumized skin appearance, and a more contoured appearance of the jawline.
  • Certain indicators of aging skin include a lessening of the flattened appearance of cheeks, appearance of nasolabial folds (drooping of skin over cheeks) and jawline sagging.
  • Improvement of skin features may be accomplished through the use of one or more skin products, or regimens of product applications, as described below.
  • the present invention allows a user to more effectively and clearly identify whether that user’s face is demonstrating a more youthful appearance, or reducing the signs of aging in the face.
  • Products may include a variety of anti aging products, which may be in the form of a lotion, cream, or other formats known in the art.
  • anti-aging products may contain one or more anti-aging active ingredients, such as retinoids, hydroxy acids and peptides.
  • retinoids include, but are not limited to, retinol, retinaldehyde, retinoic acid, retinyl palmitate, isotretinoin, tazarotene, bexarotene and Adapalene.
  • the retinoid is retinol.
  • Polyhydroxy acids are acids with multiple hydroxyl groups that can often act as moisturizers, anti-irritants and humectants.
  • Examples of polyhydroxy acid include, but are not limited to, gluconic acid lactones and aldonic acid lactones such as allonolactone, altronolactone, gluconolactone, glucoheptonolactone, mannolactone, gulonolactone, idonolactone, galactonolactone, talonolactone, lactobionic acid, maltobionic acid, and tartaric acid.
  • Alpha hydroxy acids are compounds which contain a carboxylic acid that is substituted with a hydroxyl group on the adjacent carbon atom.
  • alpha hydroxy acids include, but are not limited to, glycolic acid, malic acid, tartaric acid, pyuric acid, mandelic acid, or any combination of any of the foregoing.
  • a peptide includes dipeptides, such as those N-acyldipeptide derivatives described and disclosed in US Patent Number 9,067,969, the entire contents of which are disclosed herein by reference.
  • Other cosmetic ingredients and formulations are available that can help tighten skin, or reduce the signs of aging.
  • Some of these products are applied once per day, some may be applied twice per day, some may be applied more than twice per day, either at regular or irregular intervals. Some products may be left on the skin or some may be removed after a certain length of time post application. The regimen of application of such products may vary depending upon their effectiveness and desired impact.
  • a product may be effective for one user by applying the product once per day, however, the same product may give the same effectiveness to a different user by applying the product twice per day. It would be useful to understand the effectiveness of a certain product or regimen as it is used by a particular user, and modify the product and/or regimen depending upon the actual effectiveness in that user.
  • the method described herein may be useful in determining the effectiveness of a certain product or regimen as it used by a population or group of individuals, thereby to evaluate whether the product or regimen is successful in reducing the signs of aging. Further, the method may be useful to provide direction to modify the product and/or regimen depending upon that effectiveness over the group of individuals.
  • This innovation provides a method of providing or modifying a product and/or regimen to help provide improved effectiveness to a specific user, and in some instances, the method may help generate a specific product to use for a particular user.
  • the product may include a specific ingredient or ingredients, or may include a specific level of an ingredient or ingredients.
  • the method may help determine the regimen of application of a product, e.g., where a specific user may apply the product one time per day, or two times per day, or more than two times per day.
  • Method of Determining Effectiveness There is provided herein a method of determining the effectiveness of a product, series of products, or regimens intended to have an impact on the signs of aging.
  • the method not only may aid a user in determining whether the product or regimen is effective in improving the signs of aging, but may also help guide a user to modify the product, products, or regimen(s) that the user is following.
  • the method may be repeated to determine effectiveness over time, or as changes are made to the product(s) or regimen(s).
  • the method of determining the angle of the jawline of the user begins with using an algorithm to estimate the face’s jawline landmark positions from front facing images.
  • a coordinate system can be defined using the position of the chin as a reference point. With the position of the chin, a line from the center of the chin to the center of the face can be determined and set as the y-axis.
  • the x-axis is then defined as a line from the center of the chin at a 90- degree angle from the y-axis.
  • the x-axis and y-axis can be seen in FIG. 2.
  • One or more jawline angles can be computed between the line formed from the chin to any detected jawline landmarks with respect to the x-axis as seen in FIG. 2.
  • the angles for a particular user should be computed with the same jawline landmarks, and desirably the measurement is made from time series frontal face images with consistent facial pose and camera focal length.
  • the angle measurement can be applied to any frontal facial images with the jawline clearly visible and unobstructed.
  • frontal facial images are described herein, using the jawline, it is contemplated that other angles may be useful in determining effectiveness of a product or regimen, using different points of reference, such as the side, top, or bottom of the face.
  • the step of determining the angle may be taken one or more times during a “treatment period”, which is the period of time where a user is applying a product to help treat the signs of aging.
  • the treatment period may be from the start of an application of an anti-aging product (or immediately prior to the start of such application) to completion of such application, which may be days, weeks, months, or even years.
  • the method includes assessing the efficacy of the treatment of the signs of aging and, if necessary, modifying the product and/or the regimen of application of the product.
  • treatment efficacy may be assessed and analyzed by computing the jawline angle from consistent acquired frontal face images over time.
  • a change in the angle may be seen as an improvement indicating that the product and/or regimen was successful in treating the signs of aging.
  • the angle may be measured every day, or after a set number of days of consistent use.
  • the change in angle is determined to be effective, and in this aspect, the user may continue to use the product as the user had been using it. It may be desired to repeat the angle measurement after another set time period (e.g., daily, or after a set number of days), to determine continued effectiveness.
  • the user may choose to discontinue use of the product. Even after discontinuing use of the product, angle measurement steps may be taken to determine whether the effectiveness is maintained after use.
  • the change in angle is determined to not be as large as desired for an effective outcome after the time period intended, then the aging improvement may be considered not as effective as desired.
  • the user may modify the treatment provided, including one or more of: adding or substituting products or ingredients, using a stronger form of the product, or modifying the regimen of application (e.g., use the product more often or at different time periods). Effectiveness of the product and/or regimen is determined by the change in the angle, but determination of whether the particular product or regimen is effective may depend upon the desired outcome, and may vary from person to person.
  • a desired angle modification over a set period of time may be 0.1 degree, but in another user, a desired angle modification over the same set period of time may be 0.5 degrees or more.
  • Effectiveness of the product and/or regimen may be defined as an angle change of at least 0.1 degrees, or may be an angle change of at least 0.5 degree, or may be an angle change of at least 1 degree after a set period of time.
  • effectiveness of the product and/or regimen may be defined as an angle that has increased by at least 1% compared to the starting angle, or an angle that has increased by at least 3% compared to the starting angle, or an angle that has increased by at least 5% compared to the starting angle.
  • the desired angle change is after a set period of time after the treatment period has begun, which may be one day, may be one week, may be one month, may be two months, may be three months, or may be any other desired period of time.
  • effectiveness may be defined as a statistically significant improvement over the group of users.
  • a user may have a starting jawline angle of 14.0 degrees prior to the start of the treatment period, and after 8 weeks of application with a topical leave-on composition having 0.1% benefit ingredient, at a rate of one time per day, the resulting angle may be 14.7 degrees. If effectiveness is defined as an increase in the angle of at least 0.5 degrees compared to the starting angle after 8 weeks, then the product and regimen may be deemed effective, and no change to the product or regimen is needed. The user may end the regimen, or may continue the regimen as desired. However, if effectiveness is defined as an increase in the angle of at least 1.0 degrees compared to the starting angle after 8 weeks, the product and regimen may be deemed ineffective, and the user may modify the treatment. For example, the user may use a product that has a higher amount of benefit ingredient, or may apply the product more often, or may add an additional product to the regimen, or maybe replace the benefit ingredient with an alternative product.
  • a user may have a starting jawline angle of 14.0 degrees, and after 8 weeks of application with a composition having 0.1% benefit ingredient in the product, at a rate of one time per day, the resulting angle may be 14.7 degrees. If effectiveness is defined as an increase in the angle of at least 5% compared to the starting angle after 8 weeks, then the product and regimen may be deemed effective, and no change to the product or regimen is needed. The user may end the regimen, or may continue the regimen as desired. However, if effectiveness is defined as an increase in the angle of at least 10% compared to the starting angle after 8 weeks, the product and regimen may be deemed ineffective, and the user may modify the treatment. For example, the user may use a product that has a higher amount of benefit ingredient, or may apply the product more often, or may add an additional product to the regimen, or maybe replace the benefit ingredient with an alternative product.
  • the method may be useful to evaluate the effectiveness and need for modification of treatments other than topical formulations. For example, it is known that individuals seek to improve the look of their facial features through injection of fillers, cosmetic procedures or the like. The methods described herein may be useful in determining whether such methods of treatment are effective. As such, the method may compare the angle before and after the injection of a filler, or before and after the cosmetic procedure. Angle measurements may be taken over a length of time or various lengths of time to determine how long the intended benefit result remains in the individual, and may determine when the user may receive another treatment (e.g., injection of a filler).
  • another treatment e.g., injection of a filler
  • the inventive method described herein is useful in determining whether a treatment (e.g., application of a cosmetic or therapeutic product(s) and/or treatment regimen) is effective to reduce the signs of aging.
  • the effectiveness of the treatment may be informative to the user, and in some aspects, the method may further include the step of modifying the treatment depending upon the determination of effectiveness of the product or regimen.
  • Treatment may include one or more cosmetic treatments or cosmetic procedures.
  • a treatment may include injection of one or more fillers, cosmetic procedures (including plastic surgery), the use of peel treatment, laser treatments, or light treatments.
  • Treatment may also, or may alternatively, include the application of one or more cosmetic products to the facial skin of the user, resulting in the cosmetic effect of reducing one or more signs of aging.
  • the measurement may be taken at any time during the treatment period, and compared to a baseline angle (the baseline angle being defined as an angle prior to the treatment period).
  • the method may include the step of modifying the treatment.
  • treatment includes application of one or more cosmetic products to the facial skin of the user at set times, where the product or products have a certain amount of benefit ingredient therein.
  • Modifying the treatment may include, for example, using a different product in substitution for the product being evaluated. Or it may include using a new product in addition to the product being evaluated.
  • the modification may include leaving the product on the facial skin of the user for a longer or shorter time period than the time period being evaluated.
  • the modification may include changing the amount of the benefit ingredient(s) in the product being evaluated.
  • the modification may include changing the regimen currently being used for the product being evaluated.
  • Changing the regimen may include, for example, applying more or less of the product, or applying the product more frequently or less frequently, or changing the order of application of products, or changing the product/products used. It may be desired to measure the angle more than one time during the treatment period to determine continued effectiveness.
  • the treatment may have been deemed effective, and it may have been determined that no further treatment is required, but after a period of time (e.g., three months, six months, one year, or other period), the effectiveness is determined to be reduced.
  • the user may choose to repeat the treatment, or may choose to undergo a different treatment.
  • a new treatment period may begin, and the method described herein may be repeated for the new treatment.
  • the level of efficacy may be associated with a product or packaging, such as on its label.
  • the method may include taking an image of the face of the user to which an anti-aging product should be applied, and establishing a set of points as set forth in Figure 2 above.
  • the center of the chin is determined, and the x-axis and y-axis are determined.
  • An angle from the center of the chin to a desired point on the jawline is measured compared to the x-axis, and the angle is set as the initial baseline.
  • the treatment period then begins, where a user applies a product or products at set time periods, or other treatment described above is performed on the face.
  • the set time period may be daily or multiple times per day.
  • the angle is again measured and compared to the initial baseline.
  • the difference between the baseline angle and the measured angle is calculated, and compared to a desired change in the angle.
  • the desired change in the angle is greater than the actual change in the angle (resulting in a finding of ineffective treatment), and in some aspects the desired change in the angle is equal to or less than the actual change in the angle (resulting in a finding of effective treatment).
  • a modification to the product and/or regimen may be made.
  • the modification can be any modifications set forth above, such as changing the amount of or frequency of product applied to the skin, or replacing with a different product, or adding another product to the regimen, or increasing or decreasing the active amount of the benefit ingredient, or alternatively, other non-topical treatments may be performed as described above.
  • the angle is again measured and compared to the baseline, as well as to any other angle measurements taken. For example, it may be useful to compare the new angle measurement to the most recent previous angle measurement, and determine the change. If the desired change in the angle is greater than the actual change in the angle, then another modification to the product and/or regimen may be made.
  • the angle measurement and comparison may be repeated as many times as needed, until a desired angle change is seen.
  • the product and/or regimen may be modified as needed to provide a product and/or regimen that results in an angle change that is equal to or close to the desired angle change.
  • the treatment period may end, if desired.
  • the angle may be determined again to evaluate whether the effective reduction in the signs of aging have been lessened (indicating signs of aging). If the angle demonstrates that the reduced signs of aging are no longer present, or have lost their effectiveness, the user may choose to undergo another treatment period, either with the same or a different product and/or regimen. In this aspect, the method described herein may be repeated if desired.
  • the Y-axis (median plane) was determined based on point #8 shown on FIG. 2B (center position of the chin) and the average of all landmark points (center of the face).
  • the X-axis was drawn at 90 degree angle from the Y-axis.
  • the jawline angle is computed between the line formed from point #8 and point #10 and the X-axis.
  • the jawline angles were used to evaluate angle at each time period and determine effectiveness of the product. As noted above, an increased angle was determined to be associated with an increased youthful appearance (and therefore reduction in the sign of aging).
  • Each user in this test used a commercially available anti-aging facial cream.
  • This product was expected to give an improvement in the signs of aging, and therefore is useful in evaluating the test method described herein. Specifically, the product was expected to provide an average improvement in the angle of 0.56 after week 6, and 0.64 after week 16, of product usage.
  • the product was applied to the face of the user, as indicated by the product, two times per day. The product was rubbed into the skin and left on without removal.
  • the average angle at baseline was 15.52 degrees
  • the average angle at week 6 was 16.09
  • at week 16 the average angle was 16.17 degrees.
  • the improvement in angle measurements at week 6 and week 16 degrees was significantly different from baseline and was determined to be effective. This demonstrates that the method of angle measurement described herein is accurate and capable of determining effectiveness.
  • the treatment used could be modified as desired or necessary. Modifications could include one or more of: adding another product, substituting with a different product, modifying the product used to either increase or decrease the percentage of benefit ingredient, or modifying the regimen to use the product more often or less often. It may be useful to take angle measurements more often to modify the product and/or regimen, if desired. Measurements taken at six weeks and sixteen weeks after beginning of treatment may be sufficient or may be modified to take measurements more or less frequently, or after a longer duration (such as with a longer treatment period).
  • Example 2 - Jawline Angle Computations Based on the Cross- Age Celebrity Dataset
  • CACD Cross-Age Celebrity Dataset
  • the average jawline angles are 23.17, 23.01 , 22.59, 22.21 , 21.82, and 21.84 for age groups 11-20, 21-30, 31-40, 41-50, 51-60, and 61 -70 year olds, respectively.
  • the jawline angle can be seen to consistently decrease with age at roughly about 0.5 degrees every 10 years.
  • FIG. 3 shows the results graphically, with the average jawline angle for each age bracket (11 -20, 21-30, 31 -40, 41 -50, 51 -60, 61 +) based on analysis of frontal images from publicly available CACD dataset.
  • the error bar represents 95% confidence interval.
  • the jawline angle is able to capture the loss of youthful appearance from the triangle of youth as seen in FIG. 3. This demonstrates that the angle decreases over time, demonstrating that the angle is associated with aging.
  • the CACD dataset in the previous example is informative of the effect of aging on the jawline angle
  • the jawline angle measurement method analysis was extended to another publicly available dataset which is not limited to celebrities, and specifically created to mitigate race bias with existing public face image datasets. This dataset is called the FairFace, which contains over 100,000 facial images with an emphasis on racial balance.
  • 8604 images were clear frontal images suitable for use with the inventive methodology.
  • FIG. 4 shows the average jawline angle for each age bracket based on analysis of frontal images from publicly available FairFace dataset.
  • the error bar represents 95% confidence interval.
  • the average jawline angles are 18.81 , 21.39, 21.40,

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medical Informatics (AREA)
  • Physics & Mathematics (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Surgery (AREA)
  • Animal Behavior & Ethology (AREA)
  • Molecular Biology (AREA)
  • Veterinary Medicine (AREA)
  • Biophysics (AREA)
  • Pathology (AREA)
  • Biomedical Technology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Dentistry (AREA)
  • Oral & Maxillofacial Surgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Primary Health Care (AREA)
  • Theoretical Computer Science (AREA)
  • General Physics & Mathematics (AREA)
  • Computer Vision & Pattern Recognition (AREA)
  • Geometry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Quality & Reliability (AREA)
  • Radiology & Medical Imaging (AREA)
  • Urology & Nephrology (AREA)
  • Chemical & Material Sciences (AREA)
  • Measuring And Recording Apparatus For Diagnosis (AREA)
  • Image Processing (AREA)
  • Processing Or Creating Images (AREA)
  • Measurement Of The Respiration, Hearing Ability, Form, And Blood Characteristics Of Living Organisms (AREA)
  • Surgical Instruments (AREA)
  • Exposure And Positioning Against Photoresist Photosensitive Materials (AREA)
  • Mechanical Treatment Of Semiconductor (AREA)
  • Exposure Of Semiconductors, Excluding Electron Or Ion Beam Exposure (AREA)

Abstract

L'invention concerne des procédés de détermination de l'efficacité de traitements de visage comprenant : la fourniture d'une image de face avant du visage avant l'utilisation du traitement ; l'identification d'un axe y du visage, l'axe y étant défini par une ligne reliant la position centrale du menton du visage par le centre du visage ; l'identification d'un axe x du visage, l'axe x étant défini par une ligne qui est positionnée à un angle de 90 degrés par rapport à l'axe y et qui passe par le centre du menton du visage ; la sélection d'un point de repère facial ; l'identification d'une ligne de repère facial, la ligne de repère facial étant définie par une ligne reliant la position centrale du menton du visage au point de repère facial ; la mesure de l'angle entre l'axe x et la ligne de repère facial ; la réalisation du traitement sur le visage ; la fourniture d'une image de face avant du visage après le traitement.
PCT/IB2022/053319 2021-04-09 2022-04-08 Procédé de détermination de l'efficacité d'un traitement sur un visage WO2022215046A1 (fr)

Priority Applications (9)

Application Number Priority Date Filing Date Title
CA3216239A CA3216239A1 (fr) 2021-04-09 2022-04-08 Procede de determination de l'efficacite d'un traitement sur un visage
KR1020237037982A KR20230169196A (ko) 2021-04-09 2022-04-08 얼굴에 대한 처치의 유효성을 결정하는 방법
US18/286,162 US20240188887A1 (en) 2021-04-09 2022-04-08 Method of Determining the Effectiveness of a Treatment on a Face
CN202280033843.4A CN117377430A (zh) 2021-04-09 2022-04-08 确定对面部进行处理的效果的方法
MX2023011926A MX2023011926A (es) 2021-04-09 2022-04-08 Método para determinar la efectividad de un tratamiento en un rostro.
EP22721123.2A EP4319632A1 (fr) 2021-04-09 2022-04-08 Procédé de détermination de l'efficacité d'un traitement sur un visage
BR112023020813A BR112023020813A2 (pt) 2021-04-09 2022-04-08 Método para determinar a eficácia de um tratamento em uma face
JP2023561745A JP2024515566A (ja) 2021-04-09 2022-04-08 顔に対する治療の有効性を決定する方法
AU2022253591A AU2022253591A1 (en) 2021-04-09 2022-04-08 Method of determining the effectiveness of a treatment on a face

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202163173261P 2021-04-09 2021-04-09
US63/173,261 2021-04-09

Publications (1)

Publication Number Publication Date
WO2022215046A1 true WO2022215046A1 (fr) 2022-10-13

Family

ID=81579978

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IB2022/053319 WO2022215046A1 (fr) 2021-04-09 2022-04-08 Procédé de détermination de l'efficacité d'un traitement sur un visage

Country Status (10)

Country Link
US (1) US20240188887A1 (fr)
EP (1) EP4319632A1 (fr)
JP (1) JP2024515566A (fr)
KR (1) KR20230169196A (fr)
CN (1) CN117377430A (fr)
AU (1) AU2022253591A1 (fr)
BR (1) BR112023020813A2 (fr)
CA (1) CA3216239A1 (fr)
MX (1) MX2023011926A (fr)
WO (1) WO2022215046A1 (fr)

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH11265443A (ja) * 1997-12-15 1999-09-28 Kao Corp 印象の評価方法及び装置
JP2001331791A (ja) * 2000-05-23 2001-11-30 Pola Chem Ind Inc 加齢パターンの鑑別方法
JP2008029573A (ja) * 2006-07-28 2008-02-14 Kao Corp 美容方法
JP2013059529A (ja) * 2011-09-14 2013-04-04 Shiseido Co Ltd 顎部のたるみの評価方法
US9067969B2 (en) 2011-10-28 2015-06-30 Ruey J. Yu N-acyldipeptide derivatives and their uses

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2755721A4 (fr) * 2011-09-15 2015-05-06 Sigma Instr Holdings Llc Système et méthode de traitement de la peau et des tissus sous-jacents pour améliorer leur santé, leur fonction et/ou leur aspect
WO2021257924A1 (fr) * 2020-06-18 2021-12-23 Allergan, Inc. Méthodes et compositions de catégorisation et/ou de traitement de la rétrusion du menton chez un sujet en ayant besoin

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH11265443A (ja) * 1997-12-15 1999-09-28 Kao Corp 印象の評価方法及び装置
JP2001331791A (ja) * 2000-05-23 2001-11-30 Pola Chem Ind Inc 加齢パターンの鑑別方法
JP2008029573A (ja) * 2006-07-28 2008-02-14 Kao Corp 美容方法
JP2013059529A (ja) * 2011-09-14 2013-04-04 Shiseido Co Ltd 顎部のたるみの評価方法
US9067969B2 (en) 2011-10-28 2015-06-30 Ruey J. Yu N-acyldipeptide derivatives and their uses

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
DAVIS E. KING: "Dlib-ml: A Machine Learning Toolkit", JOURNAL OF MACHINE LEARNING RESEARCH, vol. 10, 2009, pages 1755 - 1758

Also Published As

Publication number Publication date
JP2024515566A (ja) 2024-04-10
CA3216239A1 (fr) 2022-10-13
EP4319632A1 (fr) 2024-02-14
US20240188887A1 (en) 2024-06-13
BR112023020813A2 (pt) 2023-12-12
MX2023011926A (es) 2023-12-15
KR20230169196A (ko) 2023-12-15
CN117377430A (zh) 2024-01-09
AU2022253591A1 (en) 2023-10-19

Similar Documents

Publication Publication Date Title
Shoshani et al. The modified Fitzpatrick Wrinkle Scale: a clinical validated measurement tool for nasolabial wrinkle severity assessment
Maal et al. The accuracy of matching three-dimensional photographs with skin surfaces derived from cone-beam computed tomography
Othman et al. Three-dimensional quantitative evaluation of facial morphology in adults with unilateral cleft lip and palate, and patients without clefts
Mydlova et al. Sexual dimorphism of facial appearance in ageing human adults: a cross-sectional study
JP7153112B2 (ja) 評価方法、評価装置および評価プログラム
US20130197397A1 (en) Methods and Assessment Scales for Measuring Wrinkle Severity
US11450435B2 (en) Spinal stenosis detection and generation of spinal decompression plan
EP2682068A1 (fr) Système et procédé de génération d'une mutation de profils au moyen de données de suivi
Carruthers et al. Development and validation of a photonumeric scale for evaluation of facial fine lines
Dong et al. Assessing the influence of chin asymmetry on perceived facial esthetics with 3-dimensional images
US20150126907A1 (en) Scale and associated metric for treatment of facial wrinkles and related conditions
EP4160525A1 (fr) Procédé, dispositif, programme et système d'évaluation d'affaissement
Gassia et al. Global 3‐dimensional approach to natural rejuvenation: recommendations for perioral, nose, and ear rejuvenation
Deng et al. Facial soft tissue thickness in Yangtze River delta Han population: Accurate assessment and comparative analysis utilizing Cone-Beam CT
WO2022153340A2 (fr) Système et procédé de photographie faciale et dentaire, de détection de points de repère et de génération de conception de bouche
US20240188887A1 (en) Method of Determining the Effectiveness of a Treatment on a Face
Smith et al. Growing old: Do women and men age differently?
US20240090810A1 (en) System and method for providing neurofeedback from steady-state visual evoked potentials to target affect-biased attention for treating therapeutic outcomes such as anxiety and depression
JP6983831B2 (ja) 弛み評価方法、弛み評価装置、及び弛み評価プログラム
JP7307544B2 (ja) 皮膚透明感を評価する方法
JP5538786B2 (ja) 一過性シワの評価方法及び装置
EP2373219B1 (fr) Procédé d'évaluation et de sélection pour produits de consommation
JP2016193175A (ja) 顔の見た目印象の決定部位の抽出方法、顔の見た目印象の決定因子の抽出方法、顔の見た目印象の鑑別方法
Li et al. A real-time lightweight method to detect the sixteen brushing regions based on a 9-axis inertial sensor and random forest classifier
JP7520679B2 (ja) いきいきとした顔の度合い推定方法、いきいきとした顔の度合い推定装置、及びいきいきとした顔の度合い推定プログラム

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 22721123

Country of ref document: EP

Kind code of ref document: A1

WWE Wipo information: entry into national phase

Ref document number: AU2022253591

Country of ref document: AU

Ref document number: 2022253591

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 202317066794

Country of ref document: IN

WWE Wipo information: entry into national phase

Ref document number: MX/A/2023/011926

Country of ref document: MX

Ref document number: 2023561745

Country of ref document: JP

Ref document number: 3216239

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 18286162

Country of ref document: US

REG Reference to national code

Ref country code: BR

Ref legal event code: B01A

Ref document number: 112023020813

Country of ref document: BR

ENP Entry into the national phase

Ref document number: 2022253591

Country of ref document: AU

Date of ref document: 20220408

Kind code of ref document: A

ENP Entry into the national phase

Ref document number: 20237037982

Country of ref document: KR

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 1020237037982

Country of ref document: KR

WWE Wipo information: entry into national phase

Ref document number: 202280033843.4

Country of ref document: CN

WWE Wipo information: entry into national phase

Ref document number: 2023128305

Country of ref document: RU

Ref document number: 2022721123

Country of ref document: EP

NENP Non-entry into the national phase

Ref country code: DE

ENP Entry into the national phase

Ref document number: 2022721123

Country of ref document: EP

Effective date: 20231109

ENP Entry into the national phase

Ref document number: 112023020813

Country of ref document: BR

Kind code of ref document: A2

Effective date: 20231006